On Friday, Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares price traded between $10.93 and $11.10 during the last trading session upbeat/downbeat with +0.18% at $10.98. The shares taped a trading volume 24,236 shares as compared to its an average volume of 155,393 shares.
Bio-Path Holdings, Inc (BPTH) recently specified its financial outcomes for the second quarter ended June 30, 2019 and supplied an upgrade on current business advancements.
Financial Results for the Second Quarter Ended June 30, 2019
It has 2.96 countless impressive shares and its shares float measured at 2.74. BPTH stock cost showed weak performance of -3.77% in last 7 days, switched down -13.58% in last thirty days and it fell -66.11% in last one year.
The Company stated a net loss of $2.5 M, or $0.87 per share, for the 3 months ended June 30, 2019, contrast to a bottom line of $1.7 M, or $2.96 per share, for the three months ended June 30, 2018.
Research and advancement expenses for the 3 months ended June 30, 2019 increased to $1.5 M, contrast to $0.8 M for the 3 months ended June 30, 2018 mostly Because of the beginning of activities related to Stage 2 of our Phase 2 medical trial in AML to consist of venetoclax mix treatment with prexigebersen and 2 cohorts of patients.
General and administrative expenses for the three months ended June 30, 2019 increased to $1.0 M, contrast to $0.9 M for the 3 months ended June 30, 2018 mainly Because of increased legal charges and insurance costs.
Since June 30, 2019, the Company had cash of $17.1 M, contrast to $1.0 M at December 31, 2018. Net cash used in operating activities for the 6 months ended June 30, 2019 was $4.2 M contrast to $3.4 M for the similar period in 2018. Net cash provided by financing activities for the six months ended June 30, 2019 was $20.3 M.